Amoy NGS partners with J&J for targeted therapy assay

China-based Amoy Diagnostics Co., Ltd (300658.SZ) announced a partnership agreement with US major Johnson & Johnson (J&J)’s China unit. The pair will advance indication expansion for Amoy’s polymerase chain reaction (PCR) multi-gene diagnostic assay Wei Hui Jian by combining it with an undisclosed J&J targeted therapy in the clinical setting in China. Wei Hui Jian is a Next-Generation Sequencing (NGS)-based 10 gene diagnostic assay nodded for marketing in China in November 2018.

Amoy’s ROS1 gene fusion detection kit was paired with US major Pfizer’s Xalkori (crizotinib) in clinical studies in the Asia-Pacific region, approved in Japan, South Korea and Taiwan for marketing, and entered Japan and South Korea’s reimbursement drug lists. Wei Hui Jian joined fellow NGS-based 10 gene diagnostic assay Ai Hui Jian in becoming companion diagnostic reagents for US-based major Eli Lilly’s rearranged during transfection (RET) inhibitor LOXO-292 in clinical trials in Asia in June 2019. In November 2019, Amoy and Japan-based Eisai Co., Ltd agreed to jointly develop the latter’s cholangiocarcinoma drug.


Related news
Eli Lilly this week announced it is temporarily calling a halt to new clinical trials (CTs) worldwide to reduce stress on healthcare systems amid the ongoing COVID-19 pandemic.
The Center for Drug Evaluation (CDE) website reveals that US major Eli Lilly’s rearranged during transfection (RET) inhibitor LOXO-292 (selpercatinib) has received a tacit clinical trial nod.
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) this week cleared Takeda’s tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) for market launch, according to GBI analysis.
China-based Amoy Diagnostics Co., Ltd (300658.SZ)'s Ai Hui Jian, a Next-Generation Sequencing (NGS)-based 10 gene diagnostic assay and Wei Hui Jian, a Polymerase Chain Reaction (PCR) based multi-gene diagnostic assay are set to be used as companion diagnostics (cDXs) for LOXO-292, a rearranged during transfection (RET) inhibitor under development by US-based Loxo Oncology Inc​.
China’s Center for Drug Evaluation (CDE) website indicates that four new drug products including one biosimilar have been awarded priority review status.
Recent news
GBI recently had the opportunity to talk with Dr. Lu Xianping, the president and co-founder of one of China’s earliest innovation-focused biotechs, Shenzhen Chipscreen Bioscience.
  • 1585728801763
  • China
The outbreak of the novel coronavirus first detected in China in 2019 (2019-nCoV) and its associated disease, COVID-19, has spiralled into a generational healthcare challenge of global scale.
  • 1585728673006
  • China
US-based, China-focused biotech BeyondSpring Inc., (NASDAQ: BYSI) announced the initiation of a rolling New Drug Application (NDA) for plinabulin as a treatment for chemotherapy induced neutropenia (CIN).
  • 1585724852082
  • China
  • Drug
China-based biotech Brii Biosciences has moved in to sign up Tsinghua University and the 3rd People’s Hospital of Shenzhen to a licensing agreement, after researchers at the two institutions identified multiple neutralizing monoclonal antibodies (mAbs) with therapeutic potential against the new coronavirus SARS CoV-2 and the linked COVID-19 pneumonia.
China-based Hansoh Pharmaceutical Group Co., Ltd (HKEX.3692) released its Q4 2019 financial report.
China-based Hutchison China MediTech Ltd (Chi-Med; Nasdaq/AIM: HCM) announced the initiation of a Phase II study in China for its fibroblast growth factor receptors (FGFR) inhibitor HMPL-453 in patients with advanced malignant mesothelioma.
Analytics Snapshot

Analytics Snapshot